These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 36387404)

  • 1. Treatment of multiple synchronous canine mast cell tumours using intratumoural tigilanol tiglate.
    Brown GK; Finlay JR; Straw RC; Ziea JY; Leung B; O'Connell K; Thomson MJ; Campbell JE; Jones PD; Reddell P
    Front Vet Sci; 2022; 9():1003165. PubMed ID: 36387404
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intratumoural Treatment of 18 Cytologically Diagnosed Canine High-Grade Mast Cell Tumours With Tigilanol Tiglate.
    Brown GK; Campbell JE; Jones PD; De Ridder TR; Reddell P; Johannes CM
    Front Vet Sci; 2021; 8():675804. PubMed ID: 34513966
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tigilanol Tiglate-Mediated Margins: A Comparison With Surgical Margins in Successful Treatment of Canine Mast Cell Tumours.
    De Ridder T; Reddell P; Jones P; Brown G; Campbell J
    Front Vet Sci; 2021; 8():764800. PubMed ID: 34977208
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of the Intratumoural Anticancer Drug Tigilanol Tiglate in Two Horses.
    De Ridder T; Ruppin M; Wheeless M; Williams S; Reddell P
    Front Vet Sci; 2020; 7():639. PubMed ID: 33033726
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dose Characterization of the Investigational Anticancer Drug Tigilanol Tiglate (EBC-46) in the Local Treatment of Canine Mast Cell Tumors.
    Miller J; Campbell J; Blum A; Reddell P; Gordon V; Schmidt P; Lowden S
    Front Vet Sci; 2019; 6():106. PubMed ID: 31111038
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized controlled clinical study evaluating the efficacy and safety of intratumoral treatment of canine mast cell tumors with tigilanol tiglate (EBC-46).
    De Ridder TR; Campbell JE; Burke-Schwarz C; Clegg D; Elliot EL; Geller S; Kozak W; Pittenger ST; Pruitt JB; Riehl J; White J; Wiest ML; Johannes CM; Morton J; Jones PD; Schmidt PF; Gordon V; Reddell P
    J Vet Intern Med; 2021 Jan; 35(1):415-429. PubMed ID: 32542733
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recurrence-free interval 12 months after local treatment of mast cell tumors in dogs using intratumoral injection of tigilanol tiglate.
    Jones PD; Campbell JE; Brown G; Johannes CM; Reddell P
    J Vet Intern Med; 2021 Jan; 35(1):451-455. PubMed ID: 33350511
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I dose-escalation study to determine the safety, tolerability, preliminary efficacy and pharmacokinetics of an intratumoral injection of tigilanol tiglate (EBC-46).
    Panizza BJ; de Souza P; Cooper A; Roohullah A; Karapetis CS; Lickliter JD
    EBioMedicine; 2019 Dec; 50():433-441. PubMed ID: 31810818
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Successful local treatment of a digital canine mast cell tumour with Tigilanol Tiglate].
    Gasser K
    Tierarztl Prax Ausg K Kleintiere Heimtiere; 2022 Jun; 50(3):225-231. PubMed ID: 35790169
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Wound formation, wound size, and progression of wound healing after intratumoral treatment of mast cell tumors in dogs with tigilanol tiglate.
    Reddell P; De Ridder TR; Morton JM; Jones PD; Campbell JE; Brown G; Johannes CM; Schmidt PF; Gordon V
    J Vet Intern Med; 2021 Jan; 35(1):430-441. PubMed ID: 33438258
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of tumour depth, tumour location and multiple synchronous masses on the prognosis of canine cutaneous mast cell tumours.
    Kiupel M; Webster JD; Miller RA; Kaneene JB
    J Vet Med A Physiol Pathol Clin Med; 2005 Aug; 52(6):280-6. PubMed ID: 16050909
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Practical synthesis of the therapeutic leads tigilanol tiglate and its analogues.
    Wender PA; Gentry ZO; Fanelli DJ; Luu-Nguyen QH; McAteer OD; Njoo E
    Nat Chem; 2022 Dec; 14(12):1421-1426. PubMed ID: 36192432
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence of exon 11 internal tandem duplications in the C-KIT proto-oncogene in Australian canine mast cell tumours.
    Tamlin VS; Kessell AE; Mccoy RJ; Dobson EC; Smith TS; Hebart M; Brown L; Mitrovic D; Peaston AE
    Aust Vet J; 2017 Oct; 95(10):386-391. PubMed ID: 28948627
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Progressive cutaneous viral pigmented plaques in three Hungarian Vizslas and the response of lesions to topical tigilanol tiglate gel.
    Hansen N; Nicholas N; Pack G; Mackie JT; Shipstone M; Munday JS; Reddell P; Orbell G; Malik R
    Vet Med Sci; 2018 Feb; 4(1):53-62. PubMed ID: 29468081
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of a modified proportional margin approach for complete surgical excision of canine cutaneous mast cell tumours and its association with clinical outcome.
    Saunders H; Thomson MJ; O'Connell K; Bridges JP; Chau L
    Vet Comp Oncol; 2021 Dec; 19(4):604-615. PubMed ID: 32558125
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transcriptome analysis of the medicinally significant plant Fontainea picrosperma (Euphorbiaceae) reveals conserved biosynthetic pathways.
    Mitu SA; Cummins SF; Reddell PW; Ogbourne SM
    Fitoterapia; 2020 Oct; 146():104680. PubMed ID: 32653491
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epidemiological assessment of the risk of canine mast cell tumours based on the Kiupel two-grade malignancy classification.
    Śmiech A; Ślaska B; Łopuszyński W; Jasik A; Bochyńska D; Dąbrowski R
    Acta Vet Scand; 2018 Nov; 60(1):70. PubMed ID: 30390687
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sentinel Lymph Node Mapping with Indirect Lymphangiography for Canine Mast Cell Tumour.
    De Bonis A; Collivignarelli F; Paolini A; Falerno I; Rinaldi V; Tamburro R; Bianchi A; Terragni R; Gianfelici J; Frescura P; Dolce G; Pagni E; Bucci R; Vignoli M
    Vet Sci; 2022 Sep; 9(9):. PubMed ID: 36136700
    [TBL] [Abstract][Full Text] [Related]  

  • 19. miRNA profiles of canine cutaneous mast cell tumours with early nodal metastasis and evaluation as potential biomarkers.
    Zamarian V; Ferrari R; Stefanello D; Ceciliani F; Grieco V; Minozzi G; Chiti LE; Arigoni M; Calogero R; Lecchi C
    Sci Rep; 2020 Nov; 10(1):18918. PubMed ID: 33144602
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of Gene Biomarkers for Tigilanol Tiglate Content in
    Mitu SA; Stewart P; Tran TD; Reddell PW; Cummins SF; Ogbourne SM
    Molecules; 2022 Jun; 27(13):. PubMed ID: 35807225
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.